1. In Vivo

Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles

 
• By David Wild

In December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.

Nimbus Therapeutics Closed One of the Largest Single-Asset Deals in Biotech History • Source: Shutterstock

In December 2022, Nimbus Therapeutics, Inc. signed a near record-setting $4bn single-asset deal with Takeda Pharmaceutical Co. Ltd., providing the Japanese pharma with its highly selective allosteric Tyrosine kinase 2 (TYK2) inhibitor, now called TAK-279, and the portfolio of intellectual property around the program. (Also see "Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor" - Scrip, 13 December, 2022.)

The sale was finalized after the agent, formerly known as NDI-034858, significantly bested placebo according to topline results of a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.